Lucid Diagnostics Inc.
LUCDNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $4.7M | $4.3M | $2.4M | $377,000 | $500,000 | — |
| Operating income | −$49.6M | −$46.1M | −$48.5M | −$56.3M | −$27.4M | −$8.3M |
| Net income | −$58.0M | −$45.5M | −$52.7M | −$56.2M | −$28.1M | −$8.3M |
| Total assets | $40.4M | $30.7M | $27.3M | $32.5M | $59.0M | $2.2M |
| Total liabilities | $29.5M | $25.3M | $29.6M | $9.5M | $4.3M | $15.7M |
| Equity | $10.9M | $5.4M | −$2.3M | $23.0M | $54.7M | −$13.5M |
| EPS (diluted) | $-0.69 | $-1.05 | $-1.26 | $-1.55 | $-1.51 | — |
| Shares out. | 90.8M | 67.0M | 43.4M | 37.4M | 34.9M | 14.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1054.8%
- Net margin
- −1232.7%
- Return on equity
- −530.4%
- Return on assets
- −143.4%
- Return on capital (ROCE)
- −418.4%
- Liabilities / assets
- 73.0%
- Debt / equity
- 2.70×
- Book value / share
- $0.12
- Revenue growth (YoY)
- 8.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -28.53distress
- Accruals / assets
- −28.5%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Pavmed Inc.Activist (13D)Feb 9, 2026
- Ayrton Capital LlcPassive (13G)Feb 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Matheis DennisDirector | May 20, 2026 | Buy | 245,000 | $1.00 |
| Aklog LishanOfficer — Chief Executive Officer | Feb 20, 2026 | Grant | 2.2M | $0.00 |
| Matheis DennisDirector | Feb 20, 2026 | Grant | 123,000 | $0.00 |
| White DebraDirector | Feb 20, 2026 | Grant | 123,000 | $0.00 |
| Sparks Ronald MDirector | Feb 20, 2026 | Grant | 123,000 | $0.00 |
| Sokolov Jacque JDirector | Feb 20, 2026 | Grant | 123,000 | $0.00 |
| Palumbo John RDirector | Feb 20, 2026 | Grant | 123,000 | $0.00 |
| Lapidus StanleyDirector | Feb 20, 2026 | Grant | 123,000 | $0.00 |
| Cox James LDirector | Feb 20, 2026 | Grant | 123,000 | $0.00 |
| Mcgrath Dennis MOfficer — Chief Financial Officer | Feb 20, 2026 | Grant | 470,000 | $0.00 |
| O'Neil ShaunOfficer — President and COO | Feb 20, 2026 | Grant | 620,000 | $0.00 |
| Gordon Michael AdamOfficer — General Counsel and Secretary | Feb 20, 2026 | Grant | 300,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.6M | 7.6 | +11.4% |
| Apr 30, 2026 | 5.9M | 6.2 | -4.6% |
| Apr 15, 2026 | 6.2M | 8.5 | +4.9% |
| Mar 31, 2026 | 5.9M | 10.5 | +2.4% |
| Mar 13, 2026 | 5.8M | 8.3 | -13.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 14, 2026
- Regulation FD disclosure · Other material eventApr 24, 2026
- Entered a material agreement · Regulation FD disclosureApr 23, 2026
- Results of operations · Regulation FD disclosureMar 26, 2026
- Results of operations · Regulation FD disclosureNov 12, 2025
- Director / officer change · Regulation FD disclosureSep 25, 2025
- Regulation FD disclosure · Other material eventSep 11, 2025
- Entered a material agreement · Regulation FD disclosureSep 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 21, 2026
- 8-KMay 14, 2026
- 10-QFORM 10-QMay 13, 2026
- DEFA14AApr 30, 2026
- ARSApr 30, 2026
- DEF 14AApr 30, 2026
- 3/AAMENDED INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESApr 24, 2026
- 8-KApr 24, 2026
- 424B5Apr 23, 2026
- 8-KApr 23, 2026
- PRE 14AApr 20, 2026
- 3INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESApr 13, 2026
- S-8Apr 3, 2026
- S-8Apr 3, 2026
- EFFECTMar 26, 2026